Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats
Current treatment of nerve agent poisoning with ionotropic drugs proves inadequate, and alternative treatment strategies are searched for. Based on positive findings with metabotropic glutamate modulators in microinfusion studies, the present study was initiated to examine anticonvulsant effects of...
Gespeichert in:
Veröffentlicht in: | European journal of pharmacology 2013-10, Vol.718 (1-3), p.253-260 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 260 |
---|---|
container_issue | 1-3 |
container_start_page | 253 |
container_title | European journal of pharmacology |
container_volume | 718 |
creator | Myhrer, Trond Mariussen, Espen Enger, Siri Aas, Pål |
description | Current treatment of nerve agent poisoning with ionotropic drugs proves inadequate, and alternative treatment strategies are searched for. Based on positive findings with metabotropic glutamate modulators in microinfusion studies, the present study was initiated to examine anticonvulsant effects of MPEP (2-Methyl-6-(phenylethynyl)pyridine hydrochloride), a metabotropic glutamate receptor 5 antagonist, and DCG-IV ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine), a metabotropic glutamate receptor 2/3 agonist, when administered systemically in combinations with HI-6 (1-[([4-(aminocarbonyl)pyridino]methoxy)methyl]-2-[(hydroxyimino)methyl]pyridinium) and procyclidine or HI-6 and levetiracetam relative to the combination of HI-6, procyclidine, and levetiracetam. The results showed that MPEP or DCG-IV combined with HI-6 and procyclidine resulted in substantial antidotal efficacy when administered 20min after onset of seizures elicited by soman. MPEP or DCG-IV combined with HI-6 and levetiracetam did not terminate seizures and preserve lives. When given 20min before challenge with soman, DCG-IV in combination with HI-6 and procyclidine provided protection, whereas MPEP combined with HI-6 and procyclidine did not. Combinations with metabotropic glutamate receptor modulators did not achieve the same high level of antidotal efficacy as the combination of HI-6, procyclidine, and levetiracetam. MPEP alone inhibited pseudocholinesterase activity in the brain markedly. A positive correlation was found between latency to seizure onset or full protection and level of pseudocholinesterase activity in brain. MPEP and DCG-IV can serve as effective anticonvulsants against nerve agent poisoning when combined with HI-6 and procyclidine. Metabotropic glutamate receptor modulators may represent an alternative or supplement to treatment with ionotropic drugs. |
doi_str_mv | 10.1016/j.ejphar.2013.08.024 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837343674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S001429991300633X</els_id><sourcerecordid>1837343674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-35f8430f755d4ab65cec31c9c254cde5b38cb5c755a55976e6ffccf0b5f946303</originalsourceid><addsrcrecordid>eNqFkUtv1TAQRi0EoreFf4AgSzYJfibxBgldQUGqxAK6tpzJ-OKrJA62g1R-PS4pLGE1iznz0HcIecFowyhr35wbPK_fbGw4ZaKhfUO5fEQOrO90TTvGH5MDpUzWXGt9QS5TOlNKlebqKbngknKmRHsg5mhXCz57TFVw1YzZDiHHsHqoTtOW7WwzVnMYt8nmEFPllwrCtmSMFrJfTlUKs11qv4wb4Fgl9D-3iL-5aHN6Rp44OyV8_lCvyO2H91-PH-ubz9efju9uapBM51oo10tBXafUKO3QKkAQDDRwJWFENYgeBgWlbZXSXYutcwCODspp2Qoqrsjrfe8aw_cNUzazT4DTZBcMWzKsF52Qou3k_1GpKOv6kmFB5Y5CDClFdGaNfrbxzjBq7i2Ys9ktmHsLhvamWChjLx8ubMOM49-hP7EX4NUOOBuMPUWfzO2XskEVRZK1HS_E253AEtoPj9Ek8LiUiH1EyGYM_t8__AJ-aaT6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1450178071</pqid></control><display><type>article</type><title>Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Myhrer, Trond ; Mariussen, Espen ; Enger, Siri ; Aas, Pål</creator><creatorcontrib>Myhrer, Trond ; Mariussen, Espen ; Enger, Siri ; Aas, Pål</creatorcontrib><description>Current treatment of nerve agent poisoning with ionotropic drugs proves inadequate, and alternative treatment strategies are searched for. Based on positive findings with metabotropic glutamate modulators in microinfusion studies, the present study was initiated to examine anticonvulsant effects of MPEP (2-Methyl-6-(phenylethynyl)pyridine hydrochloride), a metabotropic glutamate receptor 5 antagonist, and DCG-IV ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine), a metabotropic glutamate receptor 2/3 agonist, when administered systemically in combinations with HI-6 (1-[([4-(aminocarbonyl)pyridino]methoxy)methyl]-2-[(hydroxyimino)methyl]pyridinium) and procyclidine or HI-6 and levetiracetam relative to the combination of HI-6, procyclidine, and levetiracetam. The results showed that MPEP or DCG-IV combined with HI-6 and procyclidine resulted in substantial antidotal efficacy when administered 20min after onset of seizures elicited by soman. MPEP or DCG-IV combined with HI-6 and levetiracetam did not terminate seizures and preserve lives. When given 20min before challenge with soman, DCG-IV in combination with HI-6 and procyclidine provided protection, whereas MPEP combined with HI-6 and procyclidine did not. Combinations with metabotropic glutamate receptor modulators did not achieve the same high level of antidotal efficacy as the combination of HI-6, procyclidine, and levetiracetam. MPEP alone inhibited pseudocholinesterase activity in the brain markedly. A positive correlation was found between latency to seizure onset or full protection and level of pseudocholinesterase activity in brain. MPEP and DCG-IV can serve as effective anticonvulsants against nerve agent poisoning when combined with HI-6 and procyclidine. Metabotropic glutamate receptor modulators may represent an alternative or supplement to treatment with ionotropic drugs.</description><identifier>ISSN: 0014-2999</identifier><identifier>EISSN: 1879-0712</identifier><identifier>DOI: 10.1016/j.ejphar.2013.08.024</identifier><identifier>PMID: 24021536</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Acetylcholinesterase - metabolism ; agonists ; Animals ; antagonists ; anticonvulsants ; Anticonvulsants - pharmacology ; Anticonvulsants - therapeutic use ; brain ; Butyrylcholinesterase - metabolism ; Cyclopropanes - pharmacology ; Cyclopropanes - therapeutic use ; DCG-IV ; Drug Interactions ; glutamic acid ; Glycine - analogs & derivatives ; Glycine - pharmacology ; Glycine - therapeutic use ; HI-6 ; Levetiracetam ; Male ; MPEP ; nerve tissue ; Oximes - pharmacology ; Piracetam - analogs & derivatives ; Piracetam - pharmacology ; poisoning ; Procyclidine ; Procyclidine - pharmacology ; pyridines ; Pyridines - pharmacology ; Pyridines - therapeutic use ; Pyridinium Compounds - pharmacology ; Rats ; Rats, Wistar ; Receptor, Metabotropic Glutamate 5 - agonists ; Receptor, Metabotropic Glutamate 5 - antagonists & inhibitors ; seizures ; Seizures - chemically induced ; Seizures - drug therapy ; Seizures - enzymology ; Soman ; Soman - adverse effects</subject><ispartof>European journal of pharmacology, 2013-10, Vol.718 (1-3), p.253-260</ispartof><rights>2013 Elsevier B.V.</rights><rights>2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-35f8430f755d4ab65cec31c9c254cde5b38cb5c755a55976e6ffccf0b5f946303</citedby><cites>FETCH-LOGICAL-c419t-35f8430f755d4ab65cec31c9c254cde5b38cb5c755a55976e6ffccf0b5f946303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejphar.2013.08.024$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24021536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Myhrer, Trond</creatorcontrib><creatorcontrib>Mariussen, Espen</creatorcontrib><creatorcontrib>Enger, Siri</creatorcontrib><creatorcontrib>Aas, Pål</creatorcontrib><title>Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats</title><title>European journal of pharmacology</title><addtitle>Eur J Pharmacol</addtitle><description>Current treatment of nerve agent poisoning with ionotropic drugs proves inadequate, and alternative treatment strategies are searched for. Based on positive findings with metabotropic glutamate modulators in microinfusion studies, the present study was initiated to examine anticonvulsant effects of MPEP (2-Methyl-6-(phenylethynyl)pyridine hydrochloride), a metabotropic glutamate receptor 5 antagonist, and DCG-IV ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine), a metabotropic glutamate receptor 2/3 agonist, when administered systemically in combinations with HI-6 (1-[([4-(aminocarbonyl)pyridino]methoxy)methyl]-2-[(hydroxyimino)methyl]pyridinium) and procyclidine or HI-6 and levetiracetam relative to the combination of HI-6, procyclidine, and levetiracetam. The results showed that MPEP or DCG-IV combined with HI-6 and procyclidine resulted in substantial antidotal efficacy when administered 20min after onset of seizures elicited by soman. MPEP or DCG-IV combined with HI-6 and levetiracetam did not terminate seizures and preserve lives. When given 20min before challenge with soman, DCG-IV in combination with HI-6 and procyclidine provided protection, whereas MPEP combined with HI-6 and procyclidine did not. Combinations with metabotropic glutamate receptor modulators did not achieve the same high level of antidotal efficacy as the combination of HI-6, procyclidine, and levetiracetam. MPEP alone inhibited pseudocholinesterase activity in the brain markedly. A positive correlation was found between latency to seizure onset or full protection and level of pseudocholinesterase activity in brain. MPEP and DCG-IV can serve as effective anticonvulsants against nerve agent poisoning when combined with HI-6 and procyclidine. Metabotropic glutamate receptor modulators may represent an alternative or supplement to treatment with ionotropic drugs.</description><subject>Acetylcholinesterase - metabolism</subject><subject>agonists</subject><subject>Animals</subject><subject>antagonists</subject><subject>anticonvulsants</subject><subject>Anticonvulsants - pharmacology</subject><subject>Anticonvulsants - therapeutic use</subject><subject>brain</subject><subject>Butyrylcholinesterase - metabolism</subject><subject>Cyclopropanes - pharmacology</subject><subject>Cyclopropanes - therapeutic use</subject><subject>DCG-IV</subject><subject>Drug Interactions</subject><subject>glutamic acid</subject><subject>Glycine - analogs & derivatives</subject><subject>Glycine - pharmacology</subject><subject>Glycine - therapeutic use</subject><subject>HI-6</subject><subject>Levetiracetam</subject><subject>Male</subject><subject>MPEP</subject><subject>nerve tissue</subject><subject>Oximes - pharmacology</subject><subject>Piracetam - analogs & derivatives</subject><subject>Piracetam - pharmacology</subject><subject>poisoning</subject><subject>Procyclidine</subject><subject>Procyclidine - pharmacology</subject><subject>pyridines</subject><subject>Pyridines - pharmacology</subject><subject>Pyridines - therapeutic use</subject><subject>Pyridinium Compounds - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptor, Metabotropic Glutamate 5 - agonists</subject><subject>Receptor, Metabotropic Glutamate 5 - antagonists & inhibitors</subject><subject>seizures</subject><subject>Seizures - chemically induced</subject><subject>Seizures - drug therapy</subject><subject>Seizures - enzymology</subject><subject>Soman</subject><subject>Soman - adverse effects</subject><issn>0014-2999</issn><issn>1879-0712</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkUtv1TAQRi0EoreFf4AgSzYJfibxBgldQUGqxAK6tpzJ-OKrJA62g1R-PS4pLGE1iznz0HcIecFowyhr35wbPK_fbGw4ZaKhfUO5fEQOrO90TTvGH5MDpUzWXGt9QS5TOlNKlebqKbngknKmRHsg5mhXCz57TFVw1YzZDiHHsHqoTtOW7WwzVnMYt8nmEFPllwrCtmSMFrJfTlUKs11qv4wb4Fgl9D-3iL-5aHN6Rp44OyV8_lCvyO2H91-PH-ubz9efju9uapBM51oo10tBXafUKO3QKkAQDDRwJWFENYgeBgWlbZXSXYutcwCODspp2Qoqrsjrfe8aw_cNUzazT4DTZBcMWzKsF52Qou3k_1GpKOv6kmFB5Y5CDClFdGaNfrbxzjBq7i2Ys9ktmHsLhvamWChjLx8ubMOM49-hP7EX4NUOOBuMPUWfzO2XskEVRZK1HS_E253AEtoPj9Ek8LiUiH1EyGYM_t8__AJ-aaT6</recordid><startdate>20131015</startdate><enddate>20131015</enddate><creator>Myhrer, Trond</creator><creator>Mariussen, Espen</creator><creator>Enger, Siri</creator><creator>Aas, Pål</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20131015</creationdate><title>Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats</title><author>Myhrer, Trond ; Mariussen, Espen ; Enger, Siri ; Aas, Pål</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-35f8430f755d4ab65cec31c9c254cde5b38cb5c755a55976e6ffccf0b5f946303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acetylcholinesterase - metabolism</topic><topic>agonists</topic><topic>Animals</topic><topic>antagonists</topic><topic>anticonvulsants</topic><topic>Anticonvulsants - pharmacology</topic><topic>Anticonvulsants - therapeutic use</topic><topic>brain</topic><topic>Butyrylcholinesterase - metabolism</topic><topic>Cyclopropanes - pharmacology</topic><topic>Cyclopropanes - therapeutic use</topic><topic>DCG-IV</topic><topic>Drug Interactions</topic><topic>glutamic acid</topic><topic>Glycine - analogs & derivatives</topic><topic>Glycine - pharmacology</topic><topic>Glycine - therapeutic use</topic><topic>HI-6</topic><topic>Levetiracetam</topic><topic>Male</topic><topic>MPEP</topic><topic>nerve tissue</topic><topic>Oximes - pharmacology</topic><topic>Piracetam - analogs & derivatives</topic><topic>Piracetam - pharmacology</topic><topic>poisoning</topic><topic>Procyclidine</topic><topic>Procyclidine - pharmacology</topic><topic>pyridines</topic><topic>Pyridines - pharmacology</topic><topic>Pyridines - therapeutic use</topic><topic>Pyridinium Compounds - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptor, Metabotropic Glutamate 5 - agonists</topic><topic>Receptor, Metabotropic Glutamate 5 - antagonists & inhibitors</topic><topic>seizures</topic><topic>Seizures - chemically induced</topic><topic>Seizures - drug therapy</topic><topic>Seizures - enzymology</topic><topic>Soman</topic><topic>Soman - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Myhrer, Trond</creatorcontrib><creatorcontrib>Mariussen, Espen</creatorcontrib><creatorcontrib>Enger, Siri</creatorcontrib><creatorcontrib>Aas, Pål</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>European journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Myhrer, Trond</au><au>Mariussen, Espen</au><au>Enger, Siri</au><au>Aas, Pål</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats</atitle><jtitle>European journal of pharmacology</jtitle><addtitle>Eur J Pharmacol</addtitle><date>2013-10-15</date><risdate>2013</risdate><volume>718</volume><issue>1-3</issue><spage>253</spage><epage>260</epage><pages>253-260</pages><issn>0014-2999</issn><eissn>1879-0712</eissn><abstract>Current treatment of nerve agent poisoning with ionotropic drugs proves inadequate, and alternative treatment strategies are searched for. Based on positive findings with metabotropic glutamate modulators in microinfusion studies, the present study was initiated to examine anticonvulsant effects of MPEP (2-Methyl-6-(phenylethynyl)pyridine hydrochloride), a metabotropic glutamate receptor 5 antagonist, and DCG-IV ((2S,2′R,3′R)-2-(2′,3′-dicarboxycyclopropyl)glycine), a metabotropic glutamate receptor 2/3 agonist, when administered systemically in combinations with HI-6 (1-[([4-(aminocarbonyl)pyridino]methoxy)methyl]-2-[(hydroxyimino)methyl]pyridinium) and procyclidine or HI-6 and levetiracetam relative to the combination of HI-6, procyclidine, and levetiracetam. The results showed that MPEP or DCG-IV combined with HI-6 and procyclidine resulted in substantial antidotal efficacy when administered 20min after onset of seizures elicited by soman. MPEP or DCG-IV combined with HI-6 and levetiracetam did not terminate seizures and preserve lives. When given 20min before challenge with soman, DCG-IV in combination with HI-6 and procyclidine provided protection, whereas MPEP combined with HI-6 and procyclidine did not. Combinations with metabotropic glutamate receptor modulators did not achieve the same high level of antidotal efficacy as the combination of HI-6, procyclidine, and levetiracetam. MPEP alone inhibited pseudocholinesterase activity in the brain markedly. A positive correlation was found between latency to seizure onset or full protection and level of pseudocholinesterase activity in brain. MPEP and DCG-IV can serve as effective anticonvulsants against nerve agent poisoning when combined with HI-6 and procyclidine. Metabotropic glutamate receptor modulators may represent an alternative or supplement to treatment with ionotropic drugs.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>24021536</pmid><doi>10.1016/j.ejphar.2013.08.024</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-2999 |
ispartof | European journal of pharmacology, 2013-10, Vol.718 (1-3), p.253-260 |
issn | 0014-2999 1879-0712 |
language | eng |
recordid | cdi_proquest_miscellaneous_1837343674 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Acetylcholinesterase - metabolism agonists Animals antagonists anticonvulsants Anticonvulsants - pharmacology Anticonvulsants - therapeutic use brain Butyrylcholinesterase - metabolism Cyclopropanes - pharmacology Cyclopropanes - therapeutic use DCG-IV Drug Interactions glutamic acid Glycine - analogs & derivatives Glycine - pharmacology Glycine - therapeutic use HI-6 Levetiracetam Male MPEP nerve tissue Oximes - pharmacology Piracetam - analogs & derivatives Piracetam - pharmacology poisoning Procyclidine Procyclidine - pharmacology pyridines Pyridines - pharmacology Pyridines - therapeutic use Pyridinium Compounds - pharmacology Rats Rats, Wistar Receptor, Metabotropic Glutamate 5 - agonists Receptor, Metabotropic Glutamate 5 - antagonists & inhibitors seizures Seizures - chemically induced Seizures - drug therapy Seizures - enzymology Soman Soman - adverse effects |
title | Capacities of metabotropic glutamate modulators in counteracting soman-induced seizures in rats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A54%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Capacities%20of%20metabotropic%20glutamate%20modulators%20in%20counteracting%20soman-induced%20seizures%20in%20rats&rft.jtitle=European%20journal%20of%20pharmacology&rft.au=Myhrer,%20Trond&rft.date=2013-10-15&rft.volume=718&rft.issue=1-3&rft.spage=253&rft.epage=260&rft.pages=253-260&rft.issn=0014-2999&rft.eissn=1879-0712&rft_id=info:doi/10.1016/j.ejphar.2013.08.024&rft_dat=%3Cproquest_cross%3E1837343674%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1450178071&rft_id=info:pmid/24021536&rft_els_id=S001429991300633X&rfr_iscdi=true |